Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
GHK-Cu is primarily studied for skin rejuvenation, collagen production, wound healing, and tissue repair
Innovative, cutting-edge patch technology
Lyophilised BPC-157 is stable at -20C long-term
use cautiously
C.MatthewsJ
US$ 27.47
US$ 22.23
US$ 25.73
US$ 21.52
US$ 26.86
US$ 22.95
